Article: Research from L.P. Jiang et al broadens understanding of life sciences.

According to recent research published in the journal Biotechnology and Applied Biochemistry, "Endostar, approved for the treatment of non-small-cell lung cancer by the State Food and Drug Administration in China, is a derivative of human endostatin that is modified with an additional metal-chelating sequence (MGGSHHHHH) at the N-terminus. This modification contributes to an additional zinc-binding site in the endostatin sequence."

"In the present study, zinc-binding and zinc-free endostar were compared to further characterize their biochemical and structural properties. Thermally induced denaturation was determined by monitoring changes in fluorescence emission ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!